The term of risk-sharing agreements of major anticancer drugs are again nearing expiry.

Starting with Merck’s ‘Erbitux (cetuximab), the first drug to be reimbursed with the RSA scheme in Korea, a series of other drugs are also awaiting reevaluations until 2023.

According to industry sources, the colorectal cancer treatment Erbitux’s RSA term expires in June. Also, RSA terms for Astella’s ‘Xtandi (enzalutamide),’ Amgen’s ‘Kyprolis (carfilzomib),’ Lilly’s ‘Cyramza (ramucirumab),’ Janssen’s ‘Darzalex (daratumumab),’ Biogen’s ‘Spinraza (nusinercen),’ Sanofi’s ‘Dupixent (dupilumab)’ is nearing expiry.

With reevaluations imminent, the mixed concerns held by